Literature DB >> 32265308

Vascular permeability in the fibrotic lung.

Clemens K Probst1, Sydney B Montesi1, Benjamin D Medoff1, Barry S Shea2, Rachel S Knipe1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is thought to result from aberrant tissue repair processes in response to chronic or repetitive lung injury. The origin and nature of the injury, as well as its cellular and molecular targets, are likely heterogeneous, which complicates accurate pre-clinical modelling of the disease and makes therapeutic targeting a challenge. Efforts are underway to identify central pathways in fibrogenesis which may allow targeting of aberrant repair processes regardless of the initial injury stimulus. Dysregulated endothelial permeability and vascular leak have long been studied for their role in acute lung injury and repair. Evidence that these processes are of importance to the pathogenesis of fibrotic lung disease is growing. Endothelial permeability is increased in non-fibrosing lung diseases, but it resolves in a self-limited fashion in conditions such as bacterial pneumonia and acute respiratory distress syndrome. In progressive fibrosing diseases such as IPF, permeability appears to persist, however, and may also predict mortality. In this hypothesis-generating review, we summarise available data on the role of endothelial permeability in IPF and focus on the deleterious consequences of sustained endothelial hyperpermeability in response to and during pulmonary inflammation and fibrosis. We propose that persistent permeability and vascular leak in the lung have the potential to establish and amplify the pro-fibrotic environment. Therapeutic interventions aimed at recognising and "plugging" the leak may therefore be of significant benefit for preventing the transition from lung injury to fibrosis and should be areas for future research.
Copyright ©ERS 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32265308     DOI: 10.1183/13993003.00100-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Contracting scars from fibrin drops.

Authors:  Stephen Robinson; Eric Parigoris; Jonathan Chang; Louise Hecker; Shuichi Takayama
Journal:  Integr Biol (Camb)       Date:  2022-03-21       Impact factor: 3.177

Review 2.  From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?

Authors:  Jacob E Michalski; Jonathan S Kurche; David A Schwartz
Journal:  Transl Res       Date:  2021-09-20       Impact factor: 10.171

Review 3.  Acute exacerbation of interstitial lung disease associated with rheumatic disease.

Authors:  Fabrizio Luppi; Marco Sebastiani; Carlo Salvarani; Elisabeth Bendstrup; Andreina Manfredi
Journal:  Nat Rev Rheumatol       Date:  2021-12-07       Impact factor: 20.543

Review 4.  "A Chain Only as Strong as Its Weakest Link": An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19.

Authors:  Radu Crisan-Dabija; Cristina Alice Pavel; Iolanda Valentina Popa; Andrei Tarus; Alexandru Burlacu
Journal:  J Proteome Res       Date:  2020-09-17       Impact factor: 4.466

5.  Alteration of Diffusion Capacity After SARS-CoV-2 Infection: A Pathophysiological Approach.

Authors:  Justine Frija-Masson; Catherine Bancal; Laurent Plantier; Hélène Benzaquen; Laurence Mangin; Dominique Penaud; Florence Arnoult; Martin Flamant; Marie-Pia d'Ortho
Journal:  Front Physiol       Date:  2021-03-25       Impact factor: 4.566

6.  Endothelial-Specific Loss of Sphingosine-1-Phosphate Receptor 1 Increases Vascular Permeability and Exacerbates Bleomycin-induced Pulmonary Fibrosis.

Authors:  Rachel S Knipe; Jillian J Spinney; Elizabeth A Abe; Clemens K Probst; Alicia Franklin; Amanda Logue; Francesca Giacona; Matt Drummond; Jason Griffith; Patricia L Brazee; Lida P Hariri; Sydney B Montesi; Katherine E Black; Timothy Hla; Andrew Kuo; Andreane Cartier; Eric Engelbrecht; Christina Christoffersen; Barry S Shea; Andrew M Tager; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 7.748

7.  Comparative proteomic analysis of silica-induced pulmonary fibrosis in rats based on tandem mass tag (TMT) quantitation technology.

Authors:  Cunxiang Bo; Xiao Geng; Juan Zhang; Linlin Sai; Yu Zhang; Gongchang Yu; Zhenling Zhang; Kai Liu; Zhongjun Du; Cheng Peng; Qiang Jia; Hua Shao
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

8.  Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow.

Authors:  Maximilian Ackermann; Steven J Mentzer; Martin Kolb; Danny Jonigk
Journal:  Eur Respir J       Date:  2020-11-12       Impact factor: 16.671

Review 9.  Irreversibility of Pulmonary Fibrosis.

Authors:  Qing Yang Yu; Xiao Xiao Tang
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

Review 10.  Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19.

Authors:  Shigeru Shibata; Hisatomi Arima; Kei Asayama; Satoshi Hoshide; Atsuhiro Ichihara; Toshihiko Ishimitsu; Kazuomi Kario; Takuya Kishi; Masaki Mogi; Akira Nishiyama; Mitsuru Ohishi; Takayoshi Ohkubo; Kouichi Tamura; Masami Tanaka; Eiichiro Yamamoto; Koichi Yamamoto; Hiroshi Itoh
Journal:  Hypertens Res       Date:  2020-07-31       Impact factor: 5.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.